3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Prostatic Neoplasms
10
Carcinoma, Non-Small-Cell Lung
5
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Glioma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Rectal Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Oropharyngeal Neoplasms
2
Neoplasms
2
Mouth Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Ependymoma
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Ureteral Neoplasms
1
Thyroid Nodule
1
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Watchful Waiting
×
1 year
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled